Effect of D-004, a lipid extract from the Cuban royal palm fruit, on atypical prostate hyperplasia induced by phenylephrine in rats

Drugs in R and D

Volumn 7, Issue 4, 2006, Pages 233-241

  Arruzazabala, M L ^a   Mas R ^a   Molina, V ^a   Noa, M ^a   Carbajal, D ^a   Mendoza, N ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; D 004; DRUG VEHICLE; LIPID; NORADRENALIN; PHENYLEPHRINE; PLANT EXTRACT; PROSEREN; SECOTAX; TAMSULOSIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CAGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CAPSULE; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; EPITHELIUM CELL; FRUIT; HISTOPATHOLOGY; MALE; MICTURITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SABAL; SCORING SYSTEM; URINE VOLUME;

ANIMALS; ARECACEAE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUIT; MALE; PHENYLEPHRINE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33745257236     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200607040-00003     Document Type: Article

References (42)

1. Madsen FA, Bruskewitz RC. Benign prostatic hyperplasia pathophysiology and pharmacological treatment. Curr Opin Nephrol Hypertens 1995; 4: 455-9
2. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia. Urologe A 2002; 41: 412-24
3. Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003; 61 Suppl. 1: 2-7
4. Deslypere JP, Young M, Wilson JD, et al. Testosterone and 5 α dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 1992; 88: 15-22
5. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
6. Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003; 61 Suppl. 1: 2-7
7. Deslypere JP, Young M, Wilson JD, et al. Testosterone and 5 α dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter progene. Mol Cell Endocrinol 1992; 88: 15-22
8. Djavan B, Remzi M, Erne B, et al. The pathophysiology of benign prostatic hyperplasia. Drugs Today 2002; 38: 867-76
9. Barry MJ, Roehrborn CG. Benign prostatic hyperplasia. BMJ 2001; 323: 1042-6
10. Magee JC, Schofield GG. Neurotransmission through sympathetic ganglia of spontaneously hypertensive rats. Hypertension 1992; 20: 367-73
11. Furukawa S, Yamamoto O, Tamura T, et al. Influence of efonidipine hydrochloride, calcium antagonist on the epithelium of prostates in spontaneously hypertensive rats. J Toxicol Sci 1994; 19: 213-7
12. Pool JL. Role of the sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Pract Symp Suppl 1994; 74: 13-7
13. Golomb E, Kruglikova A, Dvir D, et al. Induction of atypical prostatic hyperplasia in rats by sympathomimetic stimulation. Prostate 1998; 34: 214-21
14. Baumgarten HG, Falck B, Holstein AF, et al. Adrenergic innervation of the human testis, epididymis, ductus deferens and prostate: a fluorescence microscopic and fluorimetric study. Z Zellforsch Mikrosk Anat 1968; 90: 81-95
15. Lepor H, Tang R, Meretyk S, et al. Alpha-1 adrenoceptor subtypes in the human prostate. J Urol 1993; 149: 640-2
16. Lepor H, Tang R, Meretyk S, et al. Binding and functional properties of alpha-1 adrenoceptors in different regions of the human prostate. J Urol 1993; 150: 253-6
17. Wang JM, McKenna KE, McVary KT, et al. Requirement of innervation for the maintenance of structural and functional integrity in the rat prostate. Biol Reprod 1991; 44: 1171-6
18. Martínez-Piñeiro L, Dahiya R, Nunes LL, et al. Pelvic plexus denervation in rats causes morphologic and functional changes of the prostate. J Urol 1993; 150: 215-8
19. Yamada S, Ashizawa N, Ushijima H, et al. Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy. J Pharmacol Exp Ther 1987; 242: 326-32
20. Kawabe K, Ueno A, Takimoto Y, et al. Use of an α-blocker, YM-12617, in the treatment of benign prostatic hypertrophy: YM617 clinical study group. J Urol 1990; 144: 908-15
21. Jonlar M, Riehmann M, Bruskewitz RC. Benign prostatic hyperplasia: current pharmacological treatment. Drugs 1994; 47: 66-71
22. Yamagishi R, Akiyama K, Nakamura S, et al. Effect of KMD-3213, an α 1A- adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur J Pharmacol 1996; 315: 73-9
23. Marinese D, Patel R, Walden PD. Mechanistic investigation of the adrenergic induction of ventral prostatic hyperplasia in mice. Prostate 2003; 54: 230-7
24. Braekman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res 1994; 55: 776-86
25. Rhodes L, Primka RL, Berman C, et al. Comparison of finasteride (Proscar), a 5α reductase inhibitor, and various commercial plant extracts on in vitro and in vivo 5 α- reductase inhibition. Prostate 1993; 22: 43-51
26. Bombardelli E, Morazzoni P. Serenoa repens (Bartram) JK Small. Fitoterapia 1997; LXVIII: 99-113
27. Plosker GL, Brogden RN. Serenoa repens (Permixon): a review of its pharmacological and therapeutic efficacy in benign progene. static hyperplasia. Drugs Aging 1996; 9: 379-95
28. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 1604-9
29. Gordon AE, Shaughnessy AF. Saw palmetto for prostate disorders. Am Fam Physician 2003; 67: 1281-3
30. Marks E. Effects of Saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000; 163: 1451-6
31. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1098 patients. Prostate 1996; 29: 231-40
32. Goepel M, Hecker U, Krege S, et al. Saw palmetto extracts potently and non-competitively inhibit human alpha 1 adrenoceptors in vitro. Prostate 1999; 38: 208-15
33. Gutierrez M, Garcia de Boto MJ, Cantabrana B, et al. Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gen Pharmacol 1996; 27: 171-6
34. Odenthal KP, Rauwald HW. Lipophilic extract from Sabal serrulata inhibits contractions in smooth muscle tissue. Aktuelle Urol 1996; 27: 152-7
35. Arruzazabala ML, Carbajal D, Mas R, et al. Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on prostatic hyperplasia induced with testosterone on intact and castrated rodents. Drugs Exp Clin Res 2004; 30 (5-6): 227-33
36. Carbajal D, Arruzazabala ML, Mas R, et al. Effect of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hypertrophy induced with testosterone or dihydrotestosterone in a rat model: a randomized controlled study. Curr Ther Res 2004; 65: 505-14
37. Arruzazabala ML, Más R, Carbajal D, et al. Effect of D-004, a lipid extract from Cuban royal palm fruit, on in vitro and in vivo effects mediated by α adrenoceptors in rats. Drugs R D 2005; 6: 281-9
38. Constantinou CE. Influence of hormone treatment on prostate growth and micturition characteristics of the rat. Prostate 1996; 29: 30-5
39. Scolnik MD, Servadio C, Abramovici A. Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. J Androl 1994; 15: 287-97
40. Price DT, Schwinn DA, Lomasney JW, et al. Identification, quantification and localization of mRNA for three distinct alpha-1 adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 546-50
41. 1C. Biochem Biophys Res Commun 1994; 201: 1296-302
42. Michel MC, Grubbel B, Taguchi K, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α1 adrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996; 16: 21-8